Analyst Coverage
Disclaimer: Any opinions, estimates or forecasts regarding ResApp Health Limited’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ResApp Health Limited or its management. ResApp Health Limited does not by its reference to any analysts imply its endorsement of or concurrence with such information, conclusions or recommendations.
| Bioshares | September 18, 2017 | ResApp Tightens Up Study Protocol for Repeat US Study |
| Morgans Financial | September 1, 2017 | Waiting for trial restart |
| Bioshares | August 11, 2017 | Learnings for ResApp from US Pediatric Study |
| Morgans Financial | August 9, 2017 | Endpoints not met |
| Morgans Financial | July 7, 2017 | What’s in a cough |
| NDF Research | June 30, 2017 | First major clinical study of ResAppDx reports important data |
| Patersons Securities | June 9, 2017 | Market Update |
| Patersons Securities | March 1, 2017 | 1H17 Result, Waiting on FDA Trial Data |
| Patersons Securities | November 16, 2016 | Initiating Coverage |
| Bioshares | August 19, 2016 | Telemedicine Adoption Building |
| NDF Research | July 25, 2016 | Initiation of Coverage |
| DJ Carmichael | April 4, 2016 | Emerging ASX Technology Sector |
| DJ Carmichael | October 19, 2015 | Emerging ASX Technology Sector |
| Bioshares | October 9, 2015 | Good Early Data for ResApp |
| Bioshares | August 28, 2015 | TeleMedicine is on the Move |
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
© 2017 ResApp Health Limited. All Rights Reserved.
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations
ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.
In the United States, ResAppDx is an investigational device and is not available for sale.